Skip to main content
Premium Trial:

Request an Annual Quote

Roche NimbleGen, Affymetrix Expand Microarray IP Agreement

NEW YORK (GenomeWeb News) - Roche NimbleGen said today it has expanded a patent license agreement with Affymetrix to include diagnostic rights to array-based DNA analysis and array-based re-sequencing.
 
NimbleGen and Affymetrix originally agreed to the patent license, which gave NimbleGen the rights to patents related to the manufacture, use, and sale of nucleic acid microarrays, in October 2006. 
 
When Roche purchased NimbleGen last June for $272 million, the licensing rights were transferred to Roche NimbleGen.
 
Roche NimbleGen makes high-density arrays of long oligo probes used in studying genomic and epigenomics variation.
 
Financial terms of the latest agreement were not released.
The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.